Tallett Elizabeth E 4

What Happened Elizabeth E. Tallett, a director of Moderna, was granted 8,371 restricted stock units (RSUs) on May 6, 2026. The award is reported as a derivative grant with an acquisition price of $0.00 (transaction type A – award/grant). These RSUs convert one-for-one into common shares when they vest, so there is no immediate cash purchase or sale.

Key Details

• Transaction date: May 6, 2026; Filing date: May 8, 2026 (filed within the standard two-business-day window).
• Amount: 8,371 RSUs granted; price reported $0.00; immediate reported cash value $0.
• Vesting: The RSUs vest in full on the earlier of May 6, 2027 or Moderna’s next Annual Meeting of Shareholders, subject to continued service (see footnotes F1 and F2).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Transaction code: A = Award/Grant (derivative security). No 10b5-1 plan, tax withholding, or late-filing indicator noted in the filing excerpt.

Context RSU grants are a form of compensation and do not represent an immediate market purchase or sale; they only convert into tradable shares if and when they vest. For retail investors, such awards are routine compensation for directors and executives and do not necessarily signal a near-term change in insider sentiment. The vesting condition and one-for-one conversion mean the economic exposure is deferred until vesting occurs.